SA521431274B1 - مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي d1 - Google Patents

مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي d1

Info

Publication number
SA521431274B1
SA521431274B1 SA521431274A SA521431274A SA521431274B1 SA 521431274 B1 SA521431274 B1 SA 521431274B1 SA 521431274 A SA521431274 A SA 521431274A SA 521431274 A SA521431274 A SA 521431274A SA 521431274 B1 SA521431274 B1 SA 521431274B1
Authority
SA
Saudi Arabia
Prior art keywords
compound
formula
methyl
pharmaceutically acceptable
disease
Prior art date
Application number
SA521431274A
Other languages
Arabic (ar)
English (en)
Inventor
آن فاليد
Original Assignee
يو سي بي بيوفارما أس آر أل
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by يو سي بي بيوفارما أس آر أل filed Critical يو سي بي بيوفارما أس آر أل
Publication of SA521431274B1 publication Critical patent/SA521431274B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SA521431274A 2019-07-01 2021-12-30 مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي d1 SA521431274B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19183641 2019-07-01
PCT/EP2020/068181 WO2021001286A1 (en) 2019-07-01 2020-06-29 A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator

Publications (1)

Publication Number Publication Date
SA521431274B1 true SA521431274B1 (ar) 2024-01-09

Family

ID=67137842

Family Applications (1)

Application Number Title Priority Date Filing Date
SA521431274A SA521431274B1 (ar) 2019-07-01 2021-12-30 مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي d1

Country Status (28)

Country Link
US (1) US12358890B2 (cg-RX-API-DMAC7.html)
EP (1) EP3993795B1 (cg-RX-API-DMAC7.html)
JP (1) JP7618597B2 (cg-RX-API-DMAC7.html)
KR (1) KR102949226B1 (cg-RX-API-DMAC7.html)
CN (1) CN114008032B (cg-RX-API-DMAC7.html)
AR (1) AR119317A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020299705B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021022379A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139622A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002949A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017740A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22007557A (cg-RX-API-DMAC7.html)
ES (1) ES3069145T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260599T1 (cg-RX-API-DMAC7.html)
IL (1) IL289317B2 (cg-RX-API-DMAC7.html)
MA (1) MA56445B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021015872A (cg-RX-API-DMAC7.html)
MY (1) MY210362A (cg-RX-API-DMAC7.html)
PE (1) PE20220373A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552819A1 (cg-RX-API-DMAC7.html)
PL (1) PL3993795T3 (cg-RX-API-DMAC7.html)
RS (1) RS68243B1 (cg-RX-API-DMAC7.html)
SA (1) SA521431274B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112539XA (cg-RX-API-DMAC7.html)
TW (1) TWI842923B (cg-RX-API-DMAC7.html)
UA (1) UA130613C2 (cg-RX-API-DMAC7.html)
WO (1) WO2021001286A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202109194B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020131671A1 (en) 2018-12-18 2020-06-25 Eli Lilly And Company Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
EP4200280B1 (en) 2020-10-07 2024-02-21 Eli Lilly And Company Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators
CN117337173A (zh) * 2021-03-09 2024-01-02 伊莱利利公司 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520217A (ja) 2007-03-01 2010-06-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンh3受容体のモジュレーターとしてのテトラヒドロイソキノリン化合物
KR101284796B1 (ko) 2011-10-05 2013-07-10 (주)포인트엔지니어링 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스
US9278960B2 (en) 2011-11-03 2016-03-08 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
EA035544B1 (ru) 2014-10-08 2020-07-03 Юсб Байофарма Спрл Производные тетрагидроизохинолина
CN108884050B (zh) * 2016-04-13 2022-07-05 Ucb生物制药私人有限公司 四氢异喹啉衍生物
EP3596060B1 (en) * 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑

Also Published As

Publication number Publication date
BR112021022379A2 (pt) 2022-03-08
AU2020299705B2 (en) 2026-03-19
US12358890B2 (en) 2025-07-15
CN114008032B (zh) 2023-11-10
AU2020299705A1 (en) 2021-12-09
IL289317B2 (en) 2025-09-01
US20220251064A1 (en) 2022-08-11
CO2021017740A2 (es) 2022-01-17
IL289317A (en) 2022-02-01
JP7618597B2 (ja) 2025-01-21
KR20220029687A (ko) 2022-03-08
MX2021015872A (es) 2022-02-03
EP3993795A1 (en) 2022-05-11
TW202115009A (zh) 2021-04-16
SG11202112539XA (en) 2021-12-30
IL289317B1 (en) 2025-05-01
TWI842923B (zh) 2024-05-21
AR119317A1 (es) 2021-12-09
ZA202109194B (en) 2023-11-29
KR102949226B1 (ko) 2026-04-06
CA3139622A1 (en) 2021-01-07
PE20220373A1 (es) 2022-03-16
MA56445B1 (fr) 2026-05-26
ECSP22007557A (es) 2022-02-25
PH12021552819A1 (en) 2022-09-28
CL2021002949A1 (es) 2022-07-15
HRP20260599T1 (hr) 2026-06-05
CN114008032A (zh) 2022-02-01
MA56445A (fr) 2022-05-11
UA130613C2 (uk) 2026-04-01
MY210362A (en) 2025-09-13
PL3993795T3 (pl) 2026-07-20
EP3993795C0 (en) 2026-04-22
EP3993795B1 (en) 2026-04-22
WO2021001286A1 (en) 2021-01-07
ES3069145T3 (en) 2026-06-04
RS68243B1 (en) 2026-07-31
JP2022537994A (ja) 2022-08-31

Similar Documents

Publication Publication Date Title
SA521431279B1 (ar) D1 مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي
NZ777871A (en) Small molecule modulators of il-17
PH12016500777B1 (en) Compositions and methods for modulating farnesoid x receptors
MX2020007853A (es) Composiciones farmaceuticas para el tratamiento de fibrosis quistica.
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
GEP20207102B (en) Sulfonamides as modulators of sodium channels
UA109220C2 (uk) Похідні (4-фенілімідазол-2-іл)етиламіну як модулятори натрієвих каналів
MX387172B (es) Moduladores del receptor x farnesoide.
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
ECSP088854A (es) Moduladores bencimidazolicos de vr1
ZA202109194B (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MY181959A (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
EA201892264A1 (ru) Производные тетрагидроизохинолина
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].
EA201792594A1 (ru) Положительные аллостерические модуляторы мусаринового рецептора м1
EA201991728A1 (ru) Модуляторы аденозиновых рецепторов a
ZA202305336B (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
MX2023001906A (es) Diarilureas como moduladores alostericos de cannabinoide cb1.
MX385475B (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa
EA202191053A1 (ru) Соединения 2-формил-3-гидроксифенилоксиметила в качестве модулятора гемоглобина
BR112019024708A2 (pt) composições farmacêuticas de liberação prolongada retardada
TN2013000241A1 (en) Compositions and methods for modulating fxr